Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission

European Cytokine Network

Volumn 11, Issue 1, 2000, Pages 91-97

  Blaise, Didier ^a,j   Attal, Michel ^b   Reiffers, Josy ^c   Michallet, Mauricette ^d   Bellanger, Coralie ^e   Pico, Jose Luis ^f   Stoppa, Anne Marie ^a   Payen, Catherine ^b   Marit, Gerald ^c   Bouabdallah, Reda ^a   Sotto, Jean Jacques ^g   Rossi, Jean François ^h   Brandely, Maud ⁱ   Hercend, Thierry ⁱ   Maraninchi, Dominique ^a  

^a INSTITUT PAOLI CALMETTES   (France)

^b CHU PURPAN   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e Hopital Cochin ^*  (France)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g HÔPITAL MICHALLON   (France)

^h MONTPELLIER UNIVERSITY HOSPITAL   (France)

ⁱ SANOFI   (France)

^j AIX MARSEILLE UNIVERSITY   (France)

more..

Author keywords

Acute leukemia; Autologous bone marrow transplantation; Immunotherapy; Interleukin 2; Prospective studies

Indexed keywords

CYCLOPHOSPHAMIDE; RECOMBINANT INTERLEUKIN 2; RU 49637; UNCLASSIFIED DRUG;

ACUTE LEUKEMIA; ADULT; ANTIGEN RECOGNITION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INFUSION; DRUG TOXICITY; EFFECTOR CELL; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-2; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; REMISSION INDUCTION; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0034114681     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. 1. Reiffers J, Gaspard M H, Maraninchi D, Michallet M, Marit G, Stoppa A M, Corront B, David B, Gastaut J A, Scotto J J, Broustet A, Carcassonne N, Hollard D. 1989. Comparison of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission: a prospective controlled trial. Br. J. Haematol. 12: 57.
2. 2. Zittoun R A, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L, Leoni F, Damasio E, Visani G, Papa G, Caronia F, Hayat M, Stryckmans P, Rotoli B, Leoni P, Peetermans M E, Dardenne M, Vegna M L, Petti M C, Solbu G and S S. 1995. Autologous or allogeneic bone marrrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. N. Engl. J. Med. 332: 217.
3. 3. Cassileth P A, Harrington D P, Appelbaum F R, Lazarus H M, Rowe J M, Paietta E, Willman C, Hurd D D, Bennett J M, Blume K G, Head D R, Wiernik P H. 1998. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N. Engl. J. Med. 339: 1649.
4. 4. Maraninchi D, Blaise D, Viens P, Brandely M, Olive D, Lopez M, Sainty D, Marit G, Stoppa A M, Reiffers J, Gratecos N, Bertau-Perez P, Mannoni P, Mawas C, Hercend T, Sebahoun G, Carcassonne Y. 1991. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 78: 2182.
5. 5. Maraninchi D, Vey N, Viens P, Stoppa A M, Archimbaud E, Attal M, Baume D, Bouabdallah R, Demeoq F, Fleury J, Michallet M, Olive D, Reiffers J, Sainty D, Tabilio A, Tiberghien P, Brandely M, Hercend T, Blaise D. 1998. A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia. Leuk. Lymphoma 31: 343.
6. 6. Stoppa A M, Fossat C, Blaise D, Viens P, Brandely M, Pourreau C N, Sainty D, Novakovitch G, Miquel M, Juhan-Vague I, Maraninchi D. 1991. Interleukin-2 induces chemotactic deficiency in patients with onco-hematologic malignancies and autologous bone marrow transplantation. Eur. Cytokine Netw. 2: 231.
7. 7. Fossat C, Sainty D, Stoppa A M, Blaise D, David M, Maraninchi D, Juhan-Vague I. 1993. In vitro inhibition of interleukin-2-induced defective polymorphonuclear chemotaxis by TNF inhibitor. Eur. J. Haematol. 51: 13.
8. 8. Olive D, Lopez M, Blaise D, Viens P, Stoppa A M, Brandely M, Mawas C, Mannoni P, Maraninchi D. 1991. Cell surface expression of ICAM-1 (CD54) and LFA-3 (CD58), two adhesion molecules, is up-regulated on bone marrow leukemic blasts after in vivo administration of high-dose recombinant interleukin-2. J. Immunother. 10: 412.
9. 9. Olive D, Chambost H, Sainty D, Stoppa A M, Blaise D, el Marsafy S, Brandely M, Mannoni P, Mawas C, Maraninchi D. 1994. Modifications of leukemic blast cells induced by in vivo high-dose recombinant interleukin-2. Leukemia 8: 1230.
10. 10. Foa R. 1996. Interleukin-2 in the management of acute leukemia. (Review) Br. J. Haematol. 92: 1.
11. 11. Blaise D, Maraninchi D. 1998. Interleukin-2 in the treatment of acute leukemia. (Review) Leuk. Res. 22: 1165.
12. 12. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos A G, Mandelli F. 1994. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84: 2158.
13. 13. Reittie J E, Gottlieb D, Heslop H E, Leger O, Drexler H G, Hazlehurst G, Hoffbrand A V, Prentice H G, Brenner M K. 1989. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy. Blood 73: 1351.
14. 14. Blaise D, Olive D, Stoppa A M, Viens P, Pourreau C, Lopez M, Attal M, Jasmin C, Monges G, Mawas C, Mannoni P, Palmer P, Franks C, Philip T, Maraninchi D. 1990. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 76: 1092.
15. 15. Blaise D, Viens P, Olive D, Stoppa A M, Gaben J, Pourreau C N, Attal M, Gaspard M H, Mannoni P, Jasmin C, Palmer P, Franks C, Michel G, Mawas C, Baume D, Philip T, Maraninchi D. 1991. Recombinant interleukin-2 (r-IL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients. Eur. Cytokine Netw 2: 121.
16. 16. Blaise D, Stoppa A M, Viens P, Sainty D, Fossat C, Miquel M, Olive D, Bouabdallah R, Gabert J, Baume D, Maraninchi D. 1992. Intensive immunotherapy with recombinant IL-2 after autologous bone marrow transplantation is associated with a high incidence of bacterial infeclions [letter]. Bone Marrow Transplant. 10: 193.
17. 17. Costello R, Blaise D, Jacquemier J, Monges G, Stoppa A M, Viens P, Olive D, Bouabdallah M, Brandely M, Gastaut J A. 1995. Induction of cutaneous'graft-versus-host like' reaction by recombinant IL-2 after autologous bone marrow transplantation [letter]. Bone Marrow Transplant. 16: 199.
18. 18. Attal M, Blaise D, Marit G, Payen C, Michallet M, Vernant J P, Sauvage C, Troussard X, Nedellec G, Pico J, Huguet F, Stoppa A M, Broustet A, Sotto J J, Pris J, Maraninchi D, Reiffers J. 1995. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 86: 1619.
19. 19. Blaise D, Attal M, Pico J L, Reiffers J, Stoppa A M, Bellanger C, Molina L, Nedellec G, Vernant J P, Legros M, Gabus R, Huguet F, Brandely M, Hercend T, Olive D, Maraninchi D. 1997. The use of a sequential high dose recombinant interleukin-2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leuk. Lymphoma 25: 469.
20. 20. Dastugue N, Payen C, Lafage-Pochitaloff M, Bernard P, Leroux D, Huguet-Rigal F, Stoppa A M, Marit G, Molina L, Michallet M, Maraninchi D, Attal M, Reiffers J. 1995. Prognostic significance of karyotype in de novo adull acute myeloid leukemia. The BGMT group. Leukemia 9: 1491.
21. 21. Faderl S, Kantarjian H M, Talpaz M, Estrov Z. 1998. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. (Review) Blood 91: 3995.
22. 22. Kaplan E, Meier P. 1958. Nonparametric estimation for incomplete observations. J. Am. Stat. Assoc. 53: 457.
23. 23. Gooley T A, Leisenring W, Crowley J, Storer B E. 1999. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. (Review) Stat Med 18:695.
24. 24. Meloni G, Foa R, Tosti S, Vignetti M, Gavosto F, Mandelli F. 1990. IL-2 in the treatmenl of chronic myeloid leukemia after lymphoid blast crisis: a pilot study. Haematologica 75: 502.
25. 25. Benyunes M C, Massumoto C, York A, Higuchi C M, Buckner C D, Thompson J A, Petersen F B, Fefer A. 1993. Interleukin-2 with or without lymphokine-activated killer cells as consolidative immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 12: 159.
26. 26. Meloni G, Foa R, Vignetti M, Guarini A, Fenu S, Tosti S, Tos A G, Mandelli F. 1994. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84: 2158.
27. 27. Blaise D, Olive D, Michallet M, Marit G, Leblond V, Maraninchi D. 1995. Impairment of leukaemia-free survival by addition of interleukin-2-receptor antibody to standard graft-versus-host prophylaxis. Lancet 345: 1144.
28. + T cell activity. J. Immunol. 150: 197.
29. 29. Charbonnier A, Gaugler B, Sainty D, Lafage-Potchitaloff M, Olive D. 1999. Human acute myeloblastic leukemia differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. Eur. J. Immunol. In press.
30. 30. Mazumder A. 1997. Experimental evidence of interleukin-2 activity in bone marrow transplantation. (Review) Cancer J. Sci. Am. 3: S37.